 | | Vol. 13.06 – 15 February, 2022 |
| |
|
|
| Using knock-down by shRNA and CRISPR/dCas9, scientists demonstrated that expression of SEMA4A was essential for normal myeloma cell growth in vitro, indicating that myeloma cells cannot downregulate the protein to avoid detection.
[Blood] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers conducted a genome-wide CRISPRi-based screening of super enhancers in ETO2-GLIS2+ acute megakaryoblastic leukemia.
[Science Advances] |
|
|
|
| To dissect the dynamic regulation of Runx1 in hematopoietic development, the authors analyzed its 3D chromatin conformation in mouse embryonic stem cell differentiation cultures.
[Nature Communications] |
|
|
|
| Investigators revealed Pax5-Jak2 as an important nuclear driver of leukemogenesis by maintaining phosphorylated STAT5 levels in the nucleus.
[EMBO Journal] |
|
|
|
| Aberrant genomic localization of DOT1L was implicated in mixed lineage leukemia-rearranged leukemias, an aggressive subset of leukemias that lacked effective targeted treatments.
[Cell Reports] |
|
|
|
| The authors identified renal Klotho and inorganic phosphate as extrinsic factors that antagonistically regulated HSC maintenance in the bone marrow.
[Cell Reports] |
|
|
|
| Scientists showed that impaired miR-652-5p expression inhibited growth, promoted apoptosis of T lymphoblastic leukemia cells in vitro and prolonged overall survival in vivo.
[Cell Death & Disease] |
|
|
|
| Researchers studied the function and mechanism of Fat mass and obesity associated (FTO) on the Bort resistance of multiple myeloma.
[Cancer Gene Therapy] |
|
|
|
| The authors performed mass spectrometry analysis of APOBEC3B-interacting proteins from nuclear extracts of myeloma cell lines and identified 30 putative interacting proteins.
[Scientific Reports] |
|
|
|
| Investigators explored the presence of cell-surface associated glucose regulated proteins (GRP78) in pediatric B-ALL at diagnosis and investigated the correlation with bona fide markers of leukemia.
[Scientific Reports] |
| |
|
|
| Scientists reported the results of a multicenter, open-label, Phase I/II study of flotetuzumab in 88 adults with relapsed/refractory AML: 42 in a dose-finding segment and 46 at the recommended Phase II dose of 500 ng/kg per day.
[Blood] |
|
|
|
| Investigators evaluated the response to inotuzumab ozogamicin in 31 relapsed/refractory B cell acute lymphoblastic leukemia patients with extramedullary disease.
[Haematologica] |
|  |
|
|
|
| The authors review the key of JAK2V617F-mediated clonal hematopoiesis including identification, prevalence, and biological impacts, linking to cardiovascular diseases and the related mechanisms.
[Journal of Cardiology] |
|
|
|
|
| Foundation Medicine, Inc. announced a collaboration with Eli Lilly and Company for the development of Foundation Medicine’s tissue- and blood-based assays as companion diagnostics for RETEVMO® and other therapies in Loxo Oncology at Lilly’s pipeline.
[Foundation Medicine, Inc.] |
|
|
|
|
|
|
|
| TU Dresden – Dresden, Germany |
|
|
|
| | George Mason University – Prince William, Virginia, United States |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | Penn State College of Medicine – Hershey, Pennsylvania, United States |
|
|
|
| | University of Vermont – Burlington, Vermont, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
